23 January 2024
Kromek Group plc
("Kromek" or the "Group")
Notice of Results
Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, gives notice that it will be announcing its interim results for the six months ended 31 October 2023 on Tuesday 30 January 2024.
Dr Arnab Basu, Chief Executive Officer, and Paul Farquhar, Chief Financial Officer, will be hosting a presentation for investors at 6pm GMT on Wednesday 31 January 2024 via webinar. The webinar is open to all existing and potential shareholders. Interested parties can register to attend, and submit questions in advance, using the following link: https://forms.gle/eRXGNiuCnmH3yGov9. Participants are requested to submit questions by 12pm on 31 January 2024.
For further information, please contact:
| Kromek Group plc | |
| Arnab Basu, CEO Paul Farquhar, CFO | +44 (0)1740 626 060 |
|
| |
| Cavendish Capital Markets Limited (Nominated Adviser and Broker)? | ? |
| Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance Tim Redfern - ECM Michael Johnson/Tamar Cranford-Smith - Sales
| +44 (0)20 7220?0500
|
| | |
| Gracechurch Group (Financial PR) | |
| Harry Chathli/Claire Norbury/Henry Gamble | +44 (0)20 4582 3500
|
Kromek Group plc
Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.
The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.
In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.
The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.
Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.